Table 2.
Anticancer treatment during survival follow-up
| Parameter | TACE plus sorafenib (n = 80) | TACE alone (n = 76) | p value* |
|---|---|---|---|
| Patients with any anticancer treatment during survival follow-up, n (%) | 47 (58.8) | 58 (76.3) | 0.014 |
| Anticancer procedure, n (%) | |||
| Liver transplantation | 0 (0.0) | 0 (0.0) | |
| Resection | 1 (2.1) | 1 (1.7) | |
| Ablation | 7 (14.9) | 13 (22.4) | |
| Transarterial therapy† | 32 (68.1) | 31 (53.4) | |
| Anticancer medication, n (%) | |||
| Sorafenib | 5 (10.6) | 29 (50.0) | |
| Regorafenib | 7 (14.9) | 5 (8.6) | |
| Lenvatinib | 6 (12.8) | 3 (5.2) | |
| Ramucirumab | 2 (4.3) | 3 (5.2) | |
| Clinical trials (immunotherapy) | 4 (8.5) | 5 (8.6) | |
| Other chemotherapy | 4 (8.5) | 5 (8.6) |
Some treatment is overlapped.
*
Fisher's exact test.
†
This therapy includes drug-eluting bead-TACE or hepatic arterial infusion chemotherapy.